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The antihyperglycemic, antidiabetic, and antioxidant potentials of the methanolic extract of Garcinia pedunculata (GP) fruit in rats
were investigated.The acute antihyperglycemic effect of different doses of GP was studied in normal maleWistar rats. Diabetes was
induced by streptozotocin (STZ) injection in another cohort of maleWistar rats and they showed significantly higher blood glucose
and glycated hemoglobin (HbA1c) levels, altered lipid profiles, and lower insulin levels compared to nondiabetic control animals.
There were increased lipid peroxidation and reduced levels of cellular antioxidant enzymes in different tissues of diabetic rats.
However, oral administration of GP extracts, especially the highest dose (1000mg/kg), significantly ameliorated hyperglycemia
(42%); elevated insulin levels (165%); decreased HbA1c (29.4%); restored lipid levels (reduction in TG by 25%, TC by 15%, and
LDL-C by 75% and increase in HDL-C by 4%), liver and renal function markers, and lipid peroxidation (reduction by 52% in the
liver, 39% in the kidney, 44% in the heart, and 46% in the pancreas); and stimulated tissue antioxidant enzymes to near normalcy.
Overall, the findings suggest that GP fruit is effective against hyperglycemia and could be used in the treatment of diabetes and its
complications and other oxidative stress-mediated pathological conditions.
1. Introduction
Diabetes mellitus (DM) is a multifarious, degenerative endo-
crine disease associated with reduced insulin secretion and
activity due to damage to pancreatic 𝛽-cells and/or reduced
insulin sensitivity, ultimately affecting carbohydrate, fat, and
protein metabolism [1]. DM is a growing public health con-
cern all over the world. TheWHO has declared that approxi-
mately 220 million people will be affected in the year 2020 [2,
3]. Hence, the issue of how to control this complex disorder
warrants much concern.
Several antidiabetic drugs are available, but all of them
have many adverse side effects such as lactic acidosis, hyper-
glycemia, diarrhea, or flatulence, which impose an economic
burden [4–6]. Therefore, researchers around the world are
doing extensive research to find alternative therapies for
DM with low side effects and low cost. Medicinal plants and
their products have been considered an excellent source for
alternative medicine to treat DM by virtue of their active
phytochemical constituents.The benefits of a natural medici-
nal product may be due to a single phytocompound or, more
preferably, a synergistic effect of multiple phytochemicals.
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To date, more than 800 medicinal plants have been reported
to show antihyperglycemic activity [7]. The most common
benefits of medicinal plants are better safety profiles, good
effectiveness, wide availability, acceptability, and affordability
[8].
Garcinia pedunculata (GP) is an indigenous medicinal
plant that belongs to the family Clusiaceae and is com-
monly known as “Taikor” in Bangladesh and “Amlavetasa”
in India. Availability is especially common in Sylhet district
in Bangladesh and in Assam, Arunachal Pradesh, India. The
mature GP fruit is greenish yellow and is consumed as a
cooked vegetable, a raw fruit, or an ingredient for pickle pre-
paration [9]. It has been used locally for the ailments of
chronic catarrh, asthma, cough, bronchitis, dysentery, maldi-
gestion, and fever [10]. The fruit extract has also been
reported to possess a variety of beneficial effects such as anti-
oxidant [9, 11], antimicrobial [12], anti-inflammatory [13],
hypolipidemic [14], hepatoprotective [15], nephroprotective,
and cardioprotective activity [16]. GP fruit has been reported
to contain moisture (88.20%), protein (0.50%) 𝛽-carotene
(45.00mg/100 g), thiamine (0.03mg/100 g), and riboflavin
(0.02mg/100 g) as well as minerals (sodium 1.80, potassium
106.00, calcium 18.00, magnesium 23.00, iron 0.08, zinc 0.15,
manganese 0.23, copper 0.12, and phosphorus 17.00mg/100 g,
resp.) [9]. Recently, the antioxidant constituent of the fruit
was analyzed andwas reported to contain phenolics (5.86mg/
g of catechin), flavonoids (5.60mg/g of quercetin), and total
antioxidant activity (504 nmol/g of ascorbate) as well as
6.67mg of anthocyanin and 142.83mg of ascorbic acid per
100 g, respectively [9, 14]. In addition, the presence of a num-
ber of benzophenones including pedunculol, garcinol, and
cambogin and other organic acids, such as citric acid, hydrox-
ycitric acid, hydroxycitric acid lactone, and oxalic acid has
also been identified [17, 18]. Further insights intoGP’s efficacy
as free radical scavengers and capacity to protect cells from
lipid peroxidation have been confirmed in several studies,
thus uncovering its medicinal importance related to chronic
or degenerative diseases including diabetes [9, 19].
In our previous study, we reported the potentials of GP
fruit extracts in the regulation of blood glucose level and
positive effects on pancreatic and liver functions as well as
lipid profile in rats [20].
Therefore, considering the traditional use of the fruit as
an alternative medicine and its inherent phytoconstituents,
we aim to evaluate the antihyperglycemic, antidiabetic, and
antioxidant effects of a GP fruit extract in rats and also
to identify its potential compounds using high-performance
liquid chromatography (HPLC) analysis.
2. Materials and Methods
2.1. Chemicals. Streptozotocin (STZ) and methanol were
purchased from Sigma (Sigma-Aldrich, St. Louis, USA).
Glibenclamide was purchased from Square Pharmaceuti-
cals Ltd., Bangladesh. Ketamine was acquired from Popu-
lar Pharmaceuticals Ltd., Dhaka, Bangladesh. Glucose oxi-
dase/peroxidase reactive strips were purchased from Abbott
Diabetes Care, Inc., USA. All chemicals and reagents used in
this experiment were of analytical grade.
2.2. GP Fruit Sample Preparation. Fresh, mature GP fruits
were collected from Sylhet district of Bangladesh in March
2016. A methanolic fruit extract (25%) was prepared accord-
ing to a method described by Lanjhiyana et al. [21] with
slight modifications. Briefly, the fresh, cleaned mature fruits
were thoroughly rinsed with cold sterile water. The edible
parts were isolated carefully, cut into small pieces using a
sharp stainless steel knife, and dried in the sunlight. When
the samples were free from moisture and appeared crunchy,
they were ground into a fine powder using a blender (Jaipan
Commando, Mumbai, India).
The fine powder (200 g) was mixed with sufficient abso-
lutemethanol to dissolve it (800mL) and was kept in a shaker
(IKA400i, Germany) at 150 rpm and 30∘C for 72 hours. The
mixture was filtered withWhatman No. 1 filter paper, and the
methanol solvent was completely evaporated using a rotary
evaporator (R-215, BUCHI, Switzerland) under reduced pres-
sure (100 psi) at a controlled temperature (40∘C).The concen-
trated extract was preserved at −20∘C for subsequent use.
2.3. HPLC Analysis of Phenolic Compounds. The phenolic
compounds in GP extract were detected following previous
methods [22, 23] with slight modifications. Briefly, 5% GP
extract solution was prepared in methanol, followed by
filtration through a 0.45𝜇m syringe filter (Sartorius AG,
Germany). 20𝜇Lof the filtratewas loaded onto theHPLC sys-
tem (SPD-20AV, serial number: L20144701414AE, Shimadzu
Corporation, Kyoto, Japan) equipped with a UV detector
(SPD-20AV, serial number: L20144701414AE, Shimadzu Cor-
poration, Kyoto, Japan). A Luna Phenomenex C18 100A (150
× 4.60mm, 5𝜇m) HPLC column was used. A linear gradient
at a flow rate of 0.5mL/min was employed throughout with a
total analytical time of approximately 35min.
The binary mobile phase consisted of solvent A (ultra-
pure water with 0.1% phosphoric acid) and solvent B (pure
methanol with 0.1% phosphoric acid). Elution from the
column was achieved with the following gradient: 0 to 10min
of solvent B, increased from 35% to 55%; 10 to 25min
of solvent B, increased to 62%; 25 to 30min of solvent
B, increased to 85%; and the final composition was kept
constant up to 35min. All solvents were of HPLC grade. The
detection wavelength was fixed between 200 and 450 nm,
with specific monitoring conducted at 265 nm. The identifi-
cation of phenolic and flavonoid compounds was performed
by comparing the retention times of the analytes with the
reference standards. Phenolics which included tannic, gallic,
pyrogallol, vanillic, benzoic, and trans-cinnamic acids as
well as flavonoids (including catechin, naringin, rutin, and
quercetin) were purchased from Sigma-Aldrich (St. Louis,
Missouri, USA) and were used as reference standards.
2.4. Experimental Animals. MaleWistar rats (𝑛 = 48) weigh-
ing between 175 and 250 g (aged 16–18 weeks) were used in
this study. The animals were maintained under controlled
environmental conditions in an animal housing facility at
the Department of Biochemistry and Molecular Biology,
Jahangirnagar University, at an ambient temperature of 22 ±
3∘C and relative humidity of 44% to 56% under a 12 h/12 h
light/dark cycle. They were fed with a standard pellet rat diet
Evidence-Based Complementary and Alternative Medicine 3
along with water ad libitum. The study was conducted in
accordance with the internationally established principles of
the US guidelines (NIH publication #85–23, revised in 1985).
The experimental protocol was approved by the Biosafety,
Biosecurity & Ethical Committee of Jahangirnagar Univer-
sity.
2.5. Induction of Diabetes in Experimental Animals. Induc-
tion of diabetes in experimental animals was done after
8–10 hours of fasting by intraperitoneal injection of STZ
dissolved in 0.1M cold citrate buffer, pH4.5, at a single dose of
60mg/kg [24]. After STZ injection, the animals were allowed
to drink a 10.0% glucose solution overnight to overcome
the initial drug-induced hypoglycemia. After seven days,
rats with glycemia ≥ 250mg/dL were selected for further
experimentation.
2.6. Experimental Design
2.6.1. Evaluation of the Antihyperglycemic Effect of GP Extracts
in Normal Rats. An oral glucose tolerance test (OGTT) was
performed to observe the acute antihyperglycemic effects of
the GP fruit extracts using different sets of normal rats. Five
groups of six rats each were used in this study. Briefly, group 1
served as a normal control; group 2 served as a glibenclamide
control, orally treated once with glibenclamide at 10mg/kg;
and groups 3, 4, and 5 were orally treated once with fruit
extracts (250, 500, and 1000mg/kg, resp.).
In overnight-fasted rats, fasting blood glucose level was
measured; this time point was defined as 0min. Then, differ-
ent doses of the fruit extract (250, 500, and 1000mg/kg) were
administered orally to the appropriate groups of rats. Blood
glucose levels were measured 30min later. The animals were
then given glucose solution (2 g/kg) orally, and their glucose
tolerance was measured hourly. Blood glucose levels were
estimated using glucose oxidase/peroxidase reactive strips.
2.6.2. Experimental Groups for Antidiabetic Study. A total
of 48 male Wistar rats were acclimatized one week prior to
the experiment and randomly divided into six groups (each
group containing 8 rats) as follows:
Group 1 (Normal Control). Animals receiving only a
normal diet for 28 days.
Group 2 (Diabetic Control). Diabetic animals receiv-
ing a normal diet for 28 days.
Group 3 (Diabetic + Glibenclamide). Diabetic animals
treated with glibenclamide at a dose of 10.0mg/kg
body weight for 28 days.
Group 4 (Diabetic + GP 250). Diabetic animals treated
with methanolic extract of GP at a dose of 250mg/kg
body weight for 28 days.
Group 5 (Diabetic + GP 500). Diabetic animals treated
with methanolic extract of GP at a dose of 500mg/kg
body weight for 28 days.
Group 6 (Diabetic + GP 1000). Diabetic animals
treated with methanolic extract of GP at a dose of
1000mg/kg body weight for 28 days.
All animals received a standard laboratory diet and drink-
ing water ad libitum during the experimental period. In addi-
tion, the rats’ body weights and fasting blood glucose levels
weremeasured on aweekly basis.The animals were alsomon-
itored for any behavioral changes during the study period.
2.6.3. Evaluation of the Antihyperglycemic Effect of GPExtracts
in Rats with STZ-Induced Diabetes. An OGTT was per-
formed to investigate the effects of the GP fruit extracts
on glucose-induced hyperglycemia in rats with STZ-induced
diabetes. The blood glucose levels were measured in over-
night-fasted rats at a time point designated as 0min.The ani-
mals were then orally dosed with glucose solution (2 g/kg)
using a gavage needle, and their glucose tolerance was meas-
ured hourly for 4 hours. Blood glucose levels were estimated
by glucose oxidase/peroxidase reactive strips.
2.7. Sacrifice of Animals. At the end of the experimental
period, all rats were fasted for 15 hours before being sacri-
ficed by intraperitoneal injection of ketamine hydrochloride
(500mg/kg) [25]. Blood samples (5mL) were collected from
the inferior vena cava. In addition, selected tissue sam-
ples including the liver, kidneys, heart, and pancreas were
immediately excised from the surrounding tissues and were
subsequently weighed.
The relative organ weight was calculated by dividing the
individual weight of each organ by the final body weight
of each rat according to the following formula [26]: relative
organ weight (%) = wet organ weight/body weight × 100.
2.8. SerumPreparation. Blood samples (4mL)were placed in
dry test tubes and were allowed to coagulate at ambient tem-
perature for 30min. Serum was separated by centrifugation
at 2000 rpm for 10min.
2.9. Tissue Homogenate Preparation. Immediately following
collection, the tissue samples were washed with ice-cold
phosphate-buffered saline (PBS). The samples were homog-
enized in phosphate buffer (25mM, pH 7.4) to make approxi-
mately 10%w/v homogenates. The homogenates were cen-
trifuged at 1700 rpm for 10min, and the supernatant was col-
lected and stored at −20∘C for further biochemical analysis.
Part of each tissue sample was preserved in formalin solution
(10%) for histopathological examination.
2.10. Biochemical Analysis of Serum. Biochemical parameters
for liver function such as alanine transaminase (ALT), aspar-
tate transaminase (AST), alkaline phosphatase (ALP), lactate
dehydrogenase (LDH), 𝛾-glutamyltransferase (GGT), total
bilirubin (TB), total protein (TP), albumin (ALB), globulin
(GLB), and albumin/globulin (A/G) ratio; parameters for
kidney function such as creatinine, urea, and uric acid; and
parameters for lipid profile including total cholesterol (TC),
triglycerides (TG), and high-density lipoprotein cholesterol
(HDL-C) were determined following standard procedures
using an automated chemistry analyzer (Dimension EXL
with LM Integrated Chemistry System, Siemens Medical
Solutions Inc., USA). Another lipid profile parameter, serum
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low-density lipoprotein cholesterol (LDL-C) level, was esti-
mated based on the following Friedewald formula [27]:
LDL-C = TC −HDL-C − TG
5
. (1)
Serum insulin level was measured using a rat-specific insulin
ELISA assay kit, while hemoglobin (Hb) level was analyzed
using an automated hematology analyzer (8000i, Sysmex,
Japan). Glycosylated hemoglobin (HbA1c) levels were mea-
sured in whole blood using an automated chemistry analyzer
(Dimension EXL with LM Integrated Chemistry System,
Siemens Medical Solutions Inc., USA).
2.11. Biochemical Analysis of Tissue. Malondialdehyde
(MDA) levels were analyzed to detect lipid peroxidation
(LPO) products in the liver, kidney, heart, and pancreas
tissues of normal and treated rats. MDA is referred to as
a thiobarbituric acid reactive substance (TBARS) and was
measured with thiobarbituric acid (TBA) at 532 nm accord-
ing to the method described by Ohkawa et al. [28]. The levels
of TBARS were expressed as mmol of MDA per mg of pro-
tein.
The levels of endogenous antioxidant or antiperoxidative
enzymes, including superoxide dismutase (SOD) and glu-
tathione peroxidase (GPx), were determined in the rats’ liver,
kidney, heart, and pancreas tissues using rat-specific SOD
and GPx ELISA assay kits (CUSABIO, USA). To this end,
the tissue homogenates were recentrifuged at 12,000 rpm for
10min at 4∘C using an Eppendorf 5415D centrifuge (Ham-
burg, Germany).The clean supernatants were used for analy-
sis. The levels of SOD and GPx were expressed as pg/mL and
mIU/mL, respectively.
2.12. Histopathological Analysis. The tissue samples were
fixed in 10% neutral formalin and processed by the paraffin
embedding technique.The histopathological specimens were
cut into 5 𝜇m thick sections using a rotary microtome and
subsequently stained with hematoxylin and eosin (H&E)
dye [29]. Photomicrographs at 6100x magnification were
captured by a normal-spectrum fluorescence microscope
(Olympus DP 72) with an attached digital camera (Olympus,
Tokyo, Japan).Thepathologist performing the histopatholog-
ical evaluation was blinded to the treatment assignments of
the different study groups.
2.13. Statistical Analysis. All results were represented as
the mean ± standard deviation (SD). Data were analyzed
using Microsoft Excel 2007 (Redmond, Washington, USA),
GraphPad Prism version 6 (GraphPad Software, Inc., USA),
and SPSS (Statistical Package for the Social Sciences, version
16.0, IBM Corporation, New York, USA). All the data from
the treatment groups (including Diabetic + Glibenclamide,
Diabetic + GP 250, Diabetic + GP 500, and Diabetic + GP
1000) were compared with the results from the diabetic con-
trol group using a one-way ANOVA followed by Dunnett’s
multiple comparison test. A 𝑝 value of less than 0.05 was
considered statistically significant.
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Figure 1: Chromatogram of GP extract showing the presence of
catechin (RT: 3.427). RT: retention time.
3. Results
3.1. HPLC Analysis. A total of eleven phenolic standards
were used in this study in which seven were phenolic acids
and four were flavonoid compounds. Only a flavonoid and
catechin (13.59mg/g) were detected in GP extract while some
other peaks remained unidentified since therewere no proper
standards available (Figure 1).
3.2. Acute Effects of GP Extract on Glucose-Induced Hyper-
glycemia in Normal Rats. Blood glucose levels returned to
baseline or even lower 1 hour after glucose administration
in all animals. Animals treated with glibenclamide and fruit
extracts showed marked decreases in blood glucose level
compared with normal control animals, beginning only 1
hour after glucose administration. In particular, the rats given
glibenclamide and GP at 500 and 1000mg/kg doses showed
significant reductions in blood glucose level compared with
the normal control rats at each time point (Table 1).
3.3. The Effects of GP Extract on Glucose-Induced Hyper-
glycemia in Rats with STZ-Induced Diabetes. Blood glucose
levels were significantly higher in rats with STZ-induced
diabetes than in normal control rats one hour after oral
administration of glucose solution. However, the administra-
tion of glibenclamide and GP at three doses caused gradual
decreases in the blood glucose levels compared with those
of diabetic control rats. The effects were significant in rats
treated with glibenclamide and GP extract at 1000mg/kg as
observed up to 4 hours after treatment (Table 2).
3.4. The Effects of GP Extract on Body Weight and Relative
Organ Weight Parameters. The effects of GP fruit extract on
body weight and relative organ weights are summarized in
Figure 2 and Table 3, respectively. During the experimental
period, the body weight of diabetic control rats gradually
decreased; however, treatment with GP extract and gliben-
clamide improved the body weight of the animals. Rats
treated with GP at 1000mg/kg showed a significant increase
in the body weight on the last week of the experiment. On the
other hand, relative organ weights were increased in diabetic
control rats but decreased in GP-treated rats. Administration
of GP extract at a dose of 1000mg/kg significantly reduced
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Table 1: The effects of GP fruit extract and glibenclamide on glucose-induced hyperglycemia in normal rats.
Groups Blood glucose level (mg/dL)
0 h 1 h 2 h 3 h 4 h 5 h
Control 108.0 ± 17.10 106.2 ± 14.58 109.8 ± 13.50 124.20 ± 9.90 115 ± 10.44 112.6 ± 8.82
Glibenclamide 104.40 ± 4.86 51.48 ± 4.50∗ 71.28 ± 2.70∗ 76.14 ± 4.50∗ 67.68 ± 4.50∗ 54.54 ± 2.07∗
GP (250mg/kg) 102.60 ± 1.98 90.00 ± 7.74 104.40 ± 2.07 117.00 ± 4.50 113.4 ± 4.51 104.4 ± 1.03
GP (500mg/kg) 99.00 ± 14.04 87.48 ± 10.44 94.14 ± 7.27 101.88 ± 10.80∗ 99 ± 6.48∗ 95.40 ± 6.48∗
GP (1000mg/kg) 104.40 ± 1.98 80.64 ± 4.50∗ 101.34 ± 9.0 108.59 ± 4.50∗ 101.98 ± 3.6∗ 98.28 ± 5.49∗
Data are represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant difference (𝑝 < 0.05) between the treatment groups and the diabetic control group.The
comparisons were made by one-way ANOVA followed by Dunnett’s multiple comparison test.
Table 2: The effects of GP fruit extract and glibenclamide on glucose-induced hyperglycemia in rats with STZ-induced diabetes.
Groups Blood glucose level (mg/dL)
0 h 1 h 2 h 3 h 4 h
Normal Control 110.31 ± 4.05# 115.12 ± 4.17# 113.32 ± 3.21 111.00 ± 6.41# 110.72 ± 5.46#
Diabetic Control 335.43 ± 19.05 353.46 ± 21.11 359.00 ± 16.30 351.4 ± 19.44 347.80 ± 27.81
Diabetic + Glibenclamide 421.90 ± 36.08 456.40 ± 45.18∗ 385.40 ± 45.18∗ 356.00 ± 16.48∗ 334.68 ± 20.45∗
Diabetic + GP (250mg/kg) 435.20 ± 38.07 467.40 ± 31.31∗ 435.40 ± 39.52 415.20 ± 26.20 407.84 ± 32.38
Diabetic + GP (500mg/kg) 343.80 ± 18.50 374.60 ± 29.56∗ 359.50 ± 21.48 335.20 ± 9.45 325.30 ± 8.30
Diabetic + GP (1000mg/kg) 320.80 ± 15.23 351.60 ± 12.09∗ 324.40 ± 18.72∗ 304.40 ± 35.43∗ 276.48 ± 24.82∗
Data are represented as the mean ± SD (𝑛 = 6). ∗ denotes a significant difference (𝑝 < 0.05) between the treatment groups and the diabetic control group; #
denotes a significant difference (𝑝 < 0.05) when the normal control group was compared to the diabetic control group. The comparisons were made by one-
way ANOVA followed by Dunnett’s multiple comparison test.
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Figure 2:The effects of GP fruit extract and glibenclamide on body
weight in normal and diabetic rats. Data are represented as themean
± SD (𝑛 = 8). ∗ denotes a significant difference (𝑝 < 0.05) between
the treatment groups and the diabetic control group. # denotes a
significant difference (𝑝 < 0.05) when the normal control group was
compared to the diabetic control group.The comparisonsweremade
by one-way ANOVA followed by Dunnett’s multiple comparison
test.
the relative weights of the liver, kidney, heart, and pancreas
compared with the diabetic control group.
3.5. The Effects of GP Extract on the Weekly Measured Blood
Glucose Levels of Normal and STZ-Induced Diabetic Rats.
Figure 3 represents the effects of GP extract on the weekly
measured blood glucose levels of normal and STZ-induced
diabetic rats during the experimental period of 28 days. The
administration of STZ injections caused a sharp increase in
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Diabetic + GP 500 Diabetic + GP 1000
7 14 21 280
Experimental time (days)
0
100
200
300
400
500
600
G
lu
co
se
 le
ve
l (
m
g/
dL
)
# # # # #
∗∗
∗
∗
∗
Figure 3: The effects of GP fruit extract and glibenclamide on
weekly measured blood glucose levels in normal and STZ-induced
diabetic rats. Data are represented as the mean ± SD (𝑛 = 8). ∗
denotes a significant difference (𝑝 < 0.05) between the treatment
groups and the diabetic control group. # denotes a significant
difference (𝑝 < 0.05) when the normal control group was compared
to the diabetic control group. The comparisons were made by one-
way ANOVA followed by Dunnett’s multiple comparison test.
the blood glucose levels of diabetic control and treated rats
compared with those of normal controls. However, treatment
with GP extract at the three selected dose levels resulted in
a marked decrease in blood glucose following the first week
and later in the experimental period. In addition, rats treated
with GP extract at 1000mg/kg and glibenclamide exhibited a
significant reduction in blood glucose levels in the third and
fourth weeks compared with diabetic control rats (𝑝 < 0.05).
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Table 3: The effects of GP fruit extract and glibenclamide on relative organ weight profile.
Groups Relative organ weight (%)
Liver Kidney Heart Pancreas
Normal Control 3.41 ± 0.29 0.61 ± 0.06 0.39 ± 0.02# 0.24 ± 0.04#
Diabetic Control 4.27 ± 0.03 0.85 ± 0.09 0.45 ± 0.04 0.42 ± 0.06
Diabetic + Glibenclamide 3.30 ± 0.32 0.77 ± 0.06 0.31 ± 0.02∗ 0.29 ± 0.07
Diabetic + GP (250mg/kg) 3.58 ± 0.45 0.84 ± 0.13 0.31 ± 0.05∗ 0.20 ± 0.07∗
Diabetic + GP (500mg/kg) 3.99 ± 0.61 0.85 ± 0.05 0.32 ± 0.02∗ 0.27 ± 0.07
Diabetic + GP (1000mg/kg) 2.80 ± 0.46∗ 0.55 ± 0.09∗ 0.32 ± 0.04∗ 0.23 ± 0.06∗
Data are represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant difference (𝑝 < 0.05) between the treatment groups and the diabetic control group; #
denotes a significant difference (𝑝 < 0.05) when the normal control group was compared to the diabetic control group. The comparisons were made by one-
way ANOVA followed by Dunnett’s multiple comparison test.
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Figure 4: The effects of GP fruit extract and glibenclamide on
insulin, HbA1c, and Hb levels in normal and STZ-induced diabetic
rats. Data are represented as the mean ± SD (𝑛 = 8). ∗ denotes
a significant difference (𝑝 < 0.05) between the treatment groups
and the diabetic control group. # denotes a significant difference
(𝑝 < 0.05) when the normal control group was compared to the
diabetic control group. The comparisons were made by one-way
ANOVA followed by Dunnett’s multiple comparison test.
3.6. Effect of GP on Serum Insulin, Glycosylated Hemoglobin
(HbA1c), and Hemoglobin Levels in Normal and STZ-Induced
Diabetic Rats. The effects of GP on serum insulin, HbA1c,
and Hb levels are presented in Figure 4. A significant
decrease in serum insulin and Hb and an increase in HbA1c
levels were observed in diabetic control rats compared with
the normal control group. However, treatment with GP
extract ameliorated these parameters in a dose-dependent
manner. Moreover, GP extract administered at the highest
dose (1000mg/kg) showed the highest potential in restoring
insulin levels and decreasing HbA1c levels compared with
those of the diabetic control group.
3.7. The Effect of GP Fruit Extract on the Lipid Profiles of
Normal and STZ-Induced Diabetic Rats. A marked increase
in circulating levels of TG, TC, and LDL-C and a decrease in
HDL-C level were observed in diabetic control rats compared
with normal control animals (Figure 5). Treatment with GP
extract was observed to significantly reduce the levels of TG,
TC, and LDL-C while increasing the HDL-C level compared
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Figure 5: The effects of GP fruit extract and glibenclamide on the
lipid profiles of normal and STZ-induced diabetic rats. Data are
represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant
difference (𝑝 < 0.05) between the treatment groups and the diabetic
control group. # denotes a significant difference (𝑝 < 0.05) when
the normal control group was compared to the diabetic control
group. The comparisons were made by one-way ANOVA followed
by Dunnett’s multiple comparison test.
with the levels measured in the STZ-challenged diabetic
control groups.
3.8. The Effects of GP on Renal Function in Normal and STZ-
Induced Diabetic Rats. The effects of GP extract and gliben-
clamide on the renal functionwere investigated bymeasuring
serum creatinine, urea, and uric acid levels (Figure 6). There
were significant increases in serum urea and uric acid and a
nonsignificant increase in creatinine levels in the diabetic rats
compared with normal controls. However, the serum levels
of these kidney function markers were improved in animals
that received GP extracts. Moreover, the animals treated
with GP extract (500 and 1000mg/kg) and glibenclamide
had significantly reduced serum urea and uric acid levels
compared with the diabetic controls.
3.9. The Effects of GP on Liver Function in Normal and STZ-
Induced Diabetic Rats. The effects of oral GP administration
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Figure 6: The effects of GP fruit extract and glibenclamide on
renal function in normal and STZ-induced diabetic rats. Data are
represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant
difference (𝑝 < 0.05) between the treatment groups and the diabetic
control group. # denotes a significant difference (𝑝 < 0.05) when
the normal control group was compared to the diabetic control
group. The comparisons were made by one-way ANOVA followed
by Dunnett’s multiple comparison test.
on liver function in diabetic rats were investigated bymeasur-
ing serum ALT, AST, ALP, GGT, and LDH activity as well as
TB, TP, ALB, and GLB levels and A/G ratio (Table 4). Serum
ALT, AST, ALP, and GGT activity and LDH and TB levels
were significantly higher in STZ-challenged diabetic rats than
in normal control rats. The rats receiving GP treatment at
500 or 1000mg/kg or glibenclamide had significantly lowered
ALT, AST, ALP, GGT, LDH, and TB levels compared with
the STZ-induced diabetic control rats. Significant reductions
in serum ALT, ALP, and LDH levels were also observed in
the 250mg/kg GP-treated group compared with the diabetic
control group.
3.10. The Effects of GP on Lipid Peroxidation (LPO) in Liver,
Kidney, Heart, and Pancreas of Normal and STZ-Induced
Diabetic Rats. Based on the investigation of oxidative stress
biomarkers, there was a significant increase in LPO levels in
STZ-induced diabetic control rats as evidenced by increases
in liver, kidney, heart, and pancreas MDA levels compared
with those of the normal control group. However, GP tended
to confer a protective effect: the animals thatwere treatedwith
fruit extracts showed a dose-dependent reduction in MDA
levels compared with the diabetic controls. Significantly
reduced LPO levels were observed in liver, kidney, heart, and
pancreas tissues from the rats treated with 1000mg/kg GP
and with glibenclamide, and the rats treated with 500mg/kg
GP had significantly reduced LPO levels in both liver and
heart tissues compared with diabetic control rats (Figure 7).
3.11. The Effects of GP on Tissue Antioxidant Enzymes (SOD
and GPx) in the Liver, Kidney, Heart, and Pancreas of Normal
and STZ-Induced Diabetic Rats. The effects of GP supple-
mentation on the activity of cellular antioxidant enzymes
including SOD and GPx in the liver, kidney, heart, and
pancreas of rats are shown in Figure 8. Diabetic rats treated
with STZ alone exhibited a significant decrease in SOD
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Figure 7: The effects of GP fruit extract and glibenclamide on lipid
peroxidation in liver, kidney, heart, and pancreas tissues. Data are
represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant
difference (𝑝 < 0.05) between the treatment groups and the diabetic
control group. # denotes a significant difference (𝑝 < 0.05) when
the normal control group was compared to the diabetic control
group. The comparisons were made by one-way ANOVA followed
by Dunnett’s multiple comparison test.
and GPx activity compared with the levels measured in the
control group. However, treatment with GP extract signifi-
cantly restored the levels of SOD activity compared with the
levels measured for the diabetic control rats. On the other
hand, diabetic rats treated with 500mg/kg or 1000mg/kg GP
showed significantly increasedGPx activity in the kidney and
heart, while rats treated with 1000mg/kg GP exhibited sig-
nificantly increased liver GPx activity, as did glibenclamide-
treated rats, compared with the diabetic control group.
3.12. Histopathological Examination of the Liver. Normal
control rats had normal livers whose hepatic lobules had a
uniform pattern of polyhedral hepatocytes radiating from
the central vein (CV) towards the periphery (Figure 9(a)).
In contrast, the livers of the GP-treated animals exhibited
histopathological changes. The rats treated with STZ alone
showed a disrupted arrangement of hepatocytes around the
CV, congestion in the central vein (CV), degeneration of
hepatocytes at the peripheral area of the central vein, and
massive vacuolization in the lobules (Figure 9(b)). The livers
of the animals in groups 3 to 6 showed improvements in all
of the histopathological features (Figures 9(c)–9(f)), with a
mild tomoderate degree of hepatocyte degeneration, vascular
congestion, and edema at all investigated doses.
3.13. Histopathological Examination of the Kidney. Normal
control rats showed normal renal parenchymal morphology
with well-defined glomeruli and tubules (Figure 10(a)). In
contrast, the rats treated with STZ alone (Figure 10(b))
showed some pathological changes including degenerated
tubular epithelium, vacuolization in some spaces, and abnor-
mally structured glomeruli (GMs) with infiltration of inflam-
matory cells. However, diabetic rats treatedwithGP extract at
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Figure 8: Effect of GP on the tissue antioxidant enzymes (a) SOD and (b) GPx in the liver, kidney, heart, and pancreas of rats in different
experimental groups. Data are represented as the mean ± SD (𝑛 = 8). ∗ denotes a significant difference (𝑝 < 0.05) between the treatment
groups and the diabetic control group. # denotes a significant difference (𝑝 < 0.05) when the normal control group was compared to the
diabetic control group. The comparisons were made by one-way ANOVA followed by Dunnett’s multiple comparison test.
each of the three doses and glibenclamide-treated rats showed
significant preservation of glomeruli architecture compared
with rats treated with STZ alone, although mild tubular
degeneration, epithelial vacuolization, and inflammatory cell
infiltration were still present (Figures 10(c)–10(f)).
3.14. Histopathological Examination of the Heart. Normal
control rats showed normal cardiac muscle fibers (Fig-
ure 11(a)). However, myocardial structural changes including
separation of cardiac muscle fibers, coagulative necrosis, and
edematous intramuscular spaces were found in the diabetic
control rats (Figure 11(b)). GP-treated rats showed marked
protection of the cardiac muscles, with increased areas of
normal muscle fibers (Figures 11(c)–11(f)).
3.15. Histopathological Examination of the Pancreas. Nor-
mal control rats showed normal islets of Langerhans (IL)
(Figure 12(a)). The rats treated with STZ alone had some
pathological changes such as IL disruption, degenerative
and necrotic changes, and vacuolization. Treatment with 250
or 500mg/kg GP caused the IL to shrink and conferred
only mild or moderate protection, respectively. Rats treated
with 1000mg/kg GP exhibited significant protection, with
markedly decreased necrosis of IL cells.
4. Discussion
To our knowledge, this is the first study to report on the
antihyperglycemic, antidiabetic, and antioxidant potentials
of GP in vivo. Weekly measurement of body weight of
the animals gives us an overview of the changes in their
body weight. Gradual weight loss is a common symptom in
DM due to degradation of structural protein and abnormal
carbohydrate metabolism [30, 31]. In this study, significant
weight loss was observed in the diabetic control group. In
contrast, significantly improved body weights compared with
the diabetic control group were found in the glibenclamide
and 1000mg/kg GP groups. This restoration of body weight
might be due to reversal of gluconeogenesis, glycogenolysis,
and proteolysis [32].The relative organ weights (liver, kidney,
heart, and pancreas) of the diabetic control rats and the
diabetic rats treated with glibenclamide and GP extracts were
higher than those of the normal control group. Daily admin-
istration of GP extract (1000mg/kg) significantly decreased
the relative organ (liver, kidney, heart, and pancreas) weights
compared with those of the diabetic control group, indicating
that GP has the potential to ameliorate diabetes by maintain-
ing or regenerating hepatocytes, renal tissue, cardiac muscle,
and islet of Langerhans histoarchitecture.
The OGTT measures the body’s ability to utilize blood
glucose. The GP fruit extract exhibited a dose-dependent
effect on the glycemic status of rats. An OGTT study in nor-
mal rats and diabetic rats showed that administration of GP
extract reduced blood glucose levels significantly, as we also
observed in rats treated with a standard drug, glibenclamide.
In the normal rats, administration of GP at 500mg/kg and
1000mg/kg doses significantly reduced blood glucose levels
within 3 to 5 hours. Diabetic rats treated with 1000mg/kg GP
showed significantly reduced blood glucose levels within 2 to
4 hours of treatment. The hypoglycemic activity of GP might
be the result of an improved insulin level, which is observed in
the GP-treated rats. This suppression of hyperglycemia may
result from the inhibition of 𝛼-glucosidase and 𝛼-amylase
enzymes by GP as reported by Sarma et al. [14].
In the present study, we found a continuous increase in
blood glucose in the diabetic control group. However, oral
administration of GP fruit extract showed significant im-
provement in blood glucose levels. Our findings indicate that
the 1000mg/kg GP dose significantly reduced blood glucose
within the thirdweek of the experiment.This finding strongly
10 Evidence-Based Complementary and Alternative Medicine
CV
(a)
CV
(b)
CV
(c)
CV
(d)
CV
(e)
CV
(f)
Figure 9: Histopathological photomicrographs of liver tissue (6100x magnification; scale bar: 20 𝜇m). (a) Normal control rats had normal
livers whose hepatic lobules had a uniform pattern of polyhedral hepatocytes radiating from the central vein (CV) towards the periphery. (b)
Diabetic control rats showed disrupted arrangement of hepatocytes around the CV, congestion in the CV, degeneration of hepatocytes at the
peripheral area of the central vein, and massive vacuolization in the lobules. (c–f) Glibenclamide- and GP-treated rats showed a remarkable
degree of preservation of the cellular arrangement with only mild vacuolization in the lobules.
supports the antidiabetic effects of GP. The antidiabetic role
of GP may result from insulin-like action such as improving
the uptake of cellular glucose or enhancing glycogenolysis.
Both insulin deficiency and resistance are responsible for
the pathogenesis of DM. Hence, increasing insulin secretion
and maintain its level within the normal physiological range
are very important for antidiabetic therapy. In this study,
administration of STZ caused damage to pancreatic 𝛽-cells
and consequently decreased the serum fasting insulin level in
rats. However, oral administration of GP extract significantly
increased serum insulin levels compared with those of the
diabetic control group in a dose-dependent manner. The
insulin levels in GP-treated diabetic rats were found to be in
the normal physiological range for rats. This indicates that
GP extract might have effects on both insulin secretion and
insulin action. In this case, the phytochemicals of GP extract
might act as stimulating agents for both insulin secretion and
insulin action. Among the compounds present inGP, garcinol
has been reported to enhance insulin action by increasing the
expression of GLUT2 and GLUT4.
Hb and HbA1c are closely associated with DM, and
HbA1c is a diagnosticmarker used to predict DMprogression
in individuals [33]. HbA1c is also widely used as a reliable
marker for estimating the degree of protein glycation during
DM [34] to indicate poorer long-term control of blood
glucose levels, leading to chronic hyperglycemic status, which
is correlated with various complications associated with DM.
We observed an elevated level of HbA1c in STZ diabetic
control rats, which was also directly proportional to the
decreased levels of total Hb. This is similar to some reports
in diabetic control experimental animals [35, 36]. However,
the oral administration of GP extract significantly improved
HbA1c andHb levels in the rats treated with 1000mg/kg.This
effect might be due to the effective control of hyperglycemia
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Figure 10: Histopathological photomicrographs of kidney tissue (6100x magnification; scale bar: 20𝜇m). (a) Normal control rats showed
normal renal parenchymal morphology with well-defined glomeruli and tubules. (b) Diabetic control rats showed abnormally structured
glomeruli (GMs) withmarked degeneration of the tubular epithelium, vacuolization, and inflammatory cell infiltration. (c–f) Glibenclamide-
and GP-treated rats showed a remarkable degree of morphological preservation with only moderate to mild degenerative changes.
by GP. This also indicates that GP might be very effective for
long-term control of DM and preventing further complica-
tions in diabetic individuals.
Catechin was detected in this study by HPLC analysis
while significant amounts of some other polyphenols were
also identified in some other studies [17, 18]. It is plausible
that the polyphenols found in GP such as catechin and
garcinol may ameliorate diabetes and its complications by
reduction in oxidative stress due to their strong antiox-
idant properties [37, 38]. Different studies have reported
that dietary polyphenols including flavonoids and phenolic
acids may inhibit 𝛼-amylase and 𝛼-glucosidase, inhibit glu-
cose absorption in the intestine by sodium-dependent glu-
cose transporter 1 (SGLT1), stimulate insulin secretion, and
reduce hepatic glucose output. Polyphenolsmay also increase
insulin-dependent glucose uptake, activate 5󸀠 adenosine
monophosphate-activated protein kinase (AMPK), mod-
ify the microbiome, and have anti-inflammatory effects.
Detailed experimentation should be conducted to identify the
exact mechanism.
The most common lipid abnormalities in DM are hyper-
triglyceridemia and hypercholesterolemia [39]. Elevated lev-
els of certain lipids are major risk factors for cardiovascular
diseases [40]. In DM, the increased level of serum lipids is
due to the uninhibited activity of lipolytic hormone on the
fat stores, primarily because of the low activity of insulin. In
the normal state, insulin activates the lipolytic actions of the
hormones on the peripheral fat depots, hydrolyzing triglyc-
erides and preventing mobilization of free fatty acids [41, 42].
In the diabetic state, lipoprotein lipase, which hydrolyzes
triglycerides, does not function properly due to the shortage
of insulin. As a result, hypertriglyceridemia occurs [43]. The
lowering of serum lipid levels through diet or drug supple-
mentation seems to be associated with a decreased risk
of cardiovascular disease and its associated complications
[44]. In this experimental study, control rats with STZ-
induced diabetes showed significantly elevated levels of TG
and cholesterol. In contrast, treatment with GP extract signif-
icantly decreased TC, TG, and LDL-C and increased HDL-C
levels in the diabetic animals. Sharma et al. reported a similar
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Figure 11: Histopathological photomicrographs of heart tissue (6100x magnification; scale bar: 20 𝜇m). (a) Normal control rats showed
normal cardiacmuscle fibers. (b) Diabetic control rats showed pathological changes includingmarked separation of cardiacmuscle fibers and
myocardial necrosis. (c–f) Glibenclamide- and GP-treated rats showed cardioprotection, with markedly increased areas of normal muscle
fibers.
hypolipidemic potential of polyphenol-rich GP extract in
high-fat diet (HFD) rats [14]. Altogether, the methanolic
extract of GP seems to possess insulin-stimulating activity,
which would be helpful to reduce the incidence of lipid-
related complications.
Diabetic nephropathy is one of the major complications
of DM. High blood sugar from DM destroys the tiny blood
vessels in the kidneys, leading to impaired renal function and
diabetic nephropathy [45]. In our present study, STZ caused
increased levels of renal function markers that indicate renal
damage in these animals. However, the daily administration
of GP, especially the 1000mg/kg dose, reduced thesemarkers,
indicating a nephroprotective effect in these diabetic animals.
Garcinol, one of the major phytoconstituents of GP, has been
reported to show significant nephroprotective effects in rats
with STZ-induced diabetes.
During DM, insulin deficiency contributes to increased
serum levels of transaminase enzymes because sufficient
amounts of amino acids stimulate the occurrence of glu-
coneogenesis and ketogenesis [46]. Increased levels of liver
enzymes such as ALT, AST, ALP, GGT, and LDH and
metabolites such as TB, TP, ALB, and GLB in the serum
are markers of liver dysfunction and/or liver mitochondrial
injury in diabetes [47]. In this study, the elevated levels of
these enzymes confirmed the existence of liver dysfunction
in the diabetic control group. Treatment withGP significantly
reversed the increased levels of liver marker enzymes such as
ALT, AST, ALP, GGT, and LDH and metabolites such as TB
and TP and restored the levels to normal values, indicating
stimulation of insulin secretion into the circulation and a
resulting hepatoprotective effect. A similar hepatoprotective
effect of GP extract was also found in HFD rats.
Oxidative stress is considered a potential contributor to
the development ofDMaswell as its complications.Oxidative
stress develops in DM through increased generation of reac-
tive oxygen species (ROS) and a decrease in ROS scavenging
capacity [48]. The excessive levels of MDA are attributed
to increased production of ROS (O2
−, H2O2, and
−OH).
Excessive lipid peroxidation causes lipid degradation that
impairs cell membrane function, resulting in tissue damage
and leading tomany pathological conditions and cytotoxicity
in the body [49, 50]. In this study, lipid peroxidation was
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Figure 12: Histopathological photomicrographs of pancreas tissue (6100x magnification; scale bar: 20𝜇m). (a) Normal control rats had
normal islets of Langerhans (IL). (b) The rats from the diabetic control group showed disruption of the IL with degenerative as well as
necrotic changes. (c–f) Glibenclamide- and GP-treated rats showed a notable degree of protection, with markedly decreased necrosis of IL
cells.
estimated in the tissues of four different organs: liver, kidney,
heart, and pancreas. As expected, STZ caused a significant
increase in lipid peroxidation as indicated by the level of
MDA (a secondary product of LPO). Treatment with a
1000mg/kg dose of GP significantly decreased the LPO levels
in all tissues.This suggests the antilipid peroxidation capacity
of GP in all of these important tissues.
Cellular antioxidant enzymes are considered the first
line of defense against free radicals [51]. Free radicals are
constantly formed in the living cells and removed by antioxi-
dant defense mechanisms. Uncontrolled generation of ROS
is involved in a number of human diseases including DM.
SOD and GPx are two important antioxidant enzymes. SOD
catalyzes the breakdown of the superoxide anion into oxygen
and hydrogen peroxide, whereas GPx reduces free hydrogen
peroxide to water. Reductions in the activity of these antiox-
idant enzymes can lead to harmful effects via the accumula-
tion of free radicals. Our findings revealed that STZ admin-
istration significantly reduced the levels of SOD and GPx
activity in the liver, kidney, heart, and pancreas in the dia-
betic control rats. However, treatment with GP fruit extract
significantly increased the levels of these antioxidant enzymes
in all the tissues compared with the diabetic control group.
This finding might result from the scavenging activity of GP,
which suppresses oxidative stress. A study has also reported
the capacity of GP fruit extract to remediate the alterations in
GSH, SOD, CAT, and MDA levels caused by HFD.
Histopathological examination of different organs
showed that STZ causes degenerative necrosis of hepatocytes,
vacuolization of the hepatic lobules, degeneration of the kid-
ney glomeruli with inflammatory infiltrates, massive separa-
tion of cardiac muscle, and necrotic damage to the myocytes
of the heart tissue and islets of Langerhans of the pancreas
in diabetic control group rats. Administration of different
doses of GP extract restored the morphology of these tis-
sues to normalcy. These histopathological findings further
confirmed the potential of GP fruit extract against STZ-
induced tissue damage.
5. Conclusions
The findings of this study indicated that oral administration
of GP in Wistar rats can ameliorate hyperglycemia, diabetes,
and diabetic complications and protect against oxidative
14 Evidence-Based Complementary and Alternative Medicine
stress-induced damage. Although establishing the mecha-
nisms behind these effects is far beyond the scope of this
study, we can certainly mention that the phytoconstituents of
GP might be responsible for these pharmacological proper-
ties. We can conclude that GP is a nontoxic source of natural
antioxidants that could be used to treat diabetes and its com-
plications. However, more detailed biochemical and molec-
ular studies should be conducted to identify the main active
ingredients in GP and their mechanistic roles as well.
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